--- canonical_name: Nefiracetam alternate_names: DM-9384, DZL-221, Translon, N-(2,6-dimethylphenyl)-2-(2-oxopyrrolidin-1-yl)acetamide canonical_topic: Nefiracetam for Health & Longevity short_topic_lc: nefiracetam creation_date: 2026-0803-1614 creator_ai_fullname: Opus 5 --- # Nefiracetam for Health & Longevity
Evidence Review created on 08/03/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 5 **Also known as:** DM-9384, DZL-221, Translon, N-(2,6-dimethylphenyl)-2-(2-oxopyrrolidin-1-yl)acetamide ## Motivation Nefiracetam is a laboratory-made compound built on the same chemical backbone as piracetam, the first substance ever marketed as a memory drug. It dissolves readily in fat, enters the brain easily, and in laboratory animals it strengthens the signalling between nerve cells that underlies learning. Interest in it comes from people who want to protect memory, mental speed, and motivation as they grow older. A Japanese pharmaceutical company developed it in the 1980s as a treatment for memory loss after stroke and in Alzheimer's disease, carried it into trials in three countries, reaching final-stage testing in Japan, and then withdrew its marketing application. The compound never reached a pharmacy shelf anywhere. It circulates today as a powder sold for laboratory use and taken by people experimenting with brain supplements. This review examines what the human and animal evidence shows about nefiracetam's effects on memory, mood, and motivation, what its documented safety findings are, how it has been dosed in trials and in practice, and where the evidence base is thin, contradictory, or produced by parties with a stake in the outcome. **[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)** ## Recommended Reading This section collects the most useful high-level sources on nefiracetam for someone who wants to go deeper than this review. - [Discover Nefiracetam as a Nootropic](https://nootropicsexpert.com/nefiracetam/) - David Tomen The most complete practitioner-facing write-up of how nefiracetam is actually used as a nootropic (a compound taken to sharpen memory, focus, or motivation) outside of research settings, including dose ranges, stacking with choline sources, and reported subjective effects. It is written from a user-advocacy standpoint, so its safety framing is markedly more relaxed than the animal toxicology literature warrants. - [Nefiracetam. Daiichi Seiyaku.](https://pubmed.ncbi.nlm.nih.gov/12090554/) - Crespi, 2002 A compact drug-development history that traces nefiracetam from Japanese phase III testing (the final, largest stage of human testing before a drug can be approved) through the US and Chinese programmes to the February 2002 withdrawal of the Japanese marketing application for insufficient efficacy. It is the clearest single account of why a compound with strong laboratory data never became a medicine. - [Pharmacological study on Alzheimer's drugs targeting calcium/calmodulin-dependent protein kinase II](https://pubmed.ncbi.nlm.nih.gov/21821968/) - Moriguchi, 2011 A mechanistic review by the researcher whose group did most of the work on how nefiracetam acts inside neurons, covering the glycine-site effect on glutamate receptors and the bell-shaped dose–response curve that peaks at extremely low concentrations. It is essential for understanding why higher doses are not necessarily better. - [Double-blind treatment of apathy in patients with poststroke depression using nefiracetam](https://pubmed.ncbi.nlm.nih.gov/19622685/) - Robinson et al., 2009 The single most positive controlled human result for nefiracetam, and the origin of its reputation for restoring drive and initiative. This trial was funded by Daiichi Pharmaceutical, the compound's developer, and one co-author was an executive at the company contracted to develop it — a financial interest that runs through nearly the whole nefiracetam evidence base. - [Testicular toxicity induced in dogs by nefiracetam, a neutrotransmission enhancer](https://pubmed.ncbi.nlm.nih.gov/15082078/) - Shimomura et al., 2004 The primary account of the reproductive toxicity that defines nefiracetam's safety profile, including the hormone measurements that identified where in testosterone synthesis the compound interferes. It was performed and published by Daiichi Pharmaceutical's own drug safety laboratory. **Note on priority sources:** No content on nefiracetam exists on foundmyfitness.com (Rhonda Patrick), peterattiamd.com (Peter Attia), hubermanlab.com (Andrew Huberman), chriskresser.com (Chris Kresser), or lifeextension.com (Life Extension Magazine). The compound is obscure enough that none of these platforms has covered it. Five sources of adequate quality were found, so the list is complete and has not been padded. ## Grokipedia - [Nefiracetam](https://grokipedia.com/page/Nefiracetam) A detailed, heavily referenced entry covering chemistry, receptor pharmacology, the preclinical amnesia-reversal literature, and the clinical trial record including the withdrawn marketing applications. Its tolerability summary is more favourable than the animal toxicology sections of this review, which is worth noting when reading it. ## Examine - [Nefiracetam benefits, dosage, and side effects](https://examine.com/supplements/nefiracetam/) Examine's entry is the most balanced short assessment available, separating the two proposed intracellular pathways and stating plainly that a single dose does nothing while repeated daily dosing is required. It is also unusually direct about the dog toxicity data and about how narrow the margin is between the doses people take and the doses that caused harm in animals. ## ConsumerLab No ConsumerLab article on nefiracetam exists. ConsumerLab tests dietary supplements sold through normal retail channels and does not cover unapproved investigational drugs distributed as laboratory research chemicals, which is the only form in which nefiracetam is available. ## Systematic Reviews A PubMed search for systematic reviews and meta-analyses of nefiracetam returned two papers, neither of which examines nefiracetam alone. - [Treatment of apathy in stroke patients: a systematic review](https://pubmed.ncbi.nlm.nih.gov/41383225/) - Ruiz-Franco et al., 2025 A pre-registered review, conducted to international reporting standards, of ten trials in 2,359 patients that assessed every reported treatment for loss of drive after stroke. It concludes that nefiracetam helped in the one trial where participants also had depression but failed in participants without depression, and it rates the overall evidence for the compound as scarce and heterogeneous. - [Comparative efficacy and acceptability of antidepressant treatment in poststroke depression: a multiple-treatments meta-analysis](https://pubmed.ncbi.nlm.nih.gov/28775189/) - Sun et al., 2017 A network meta-analysis (a method that ranks treatments by combining direct head-to-head comparisons with indirect ones) of twelve trials and 707 participants. Nefiracetam ranked last of ten antidepressant treatments for efficacy and was one of only three agents that did not beat placebo, while its dropout rate was not significantly different from placebo. ## Mechanism of Action Nefiracetam does not act on a single receptor. It is a weak positive modulator of several systems at once, meaning it does not switch anything on by itself but amplifies signals that are already occurring. - **Nicotinic acetylcholine receptors:** Nefiracetam potentiates neuronal nicotinic acetylcholine receptors (nAChRs, the fast-acting docking sites for acetylcholine, the brain's main "attention and encoding" messenger), particularly the α4β2 subtype, at nanomolar concentrations ([Zhao et al., 2001](https://pubmed.ncbi.nlm.nih.gov/11259610/)). Because many of these sit on the sending side of the synapse, the result is more neurotransmitter release per incoming signal ([Nishizaki et al., 2000](https://pubmed.ncbi.nlm.nih.gov/11039729/)). - **NMDA receptors via the glycine site:** It potentiates N-methyl-D-aspartate receptors (NMDA receptors, the glutamate-sensing channels that convert repeated activity into lasting synaptic change) by acting at their glycine co-activation site and by reducing the magnesium plug that normally blocks them, an effect mediated through protein kinase C (PKC, an enzyme that switches other proteins on by tagging them with phosphate) ([Moriguchi et al., 2007](https://pubmed.ncbi.nlm.nih.gov/17095583/)). - **Calcium channels and the memory enzyme cascade:** It prolongs opening of L-type voltage-gated calcium channels, and the resulting calcium entry activates calcium/calmodulin-dependent protein kinase II (CaMKII, the enzyme widely regarded as the molecular switch for memory storage). CaMKII then tags the GluA1 subunit of the AMPA receptor (AMPA receptors are the fast channels that carry most ordinary signalling between neurons; GluA1 is the part that sets how strongly a synapse responds), producing enhanced long-term potentiation (LTP, the durable strengthening of a synapse that is the cellular basis of learning) ([Moriguchi et al., 2008](https://pubmed.ncbi.nlm.nih.gov/18445137/); [Yamada et al., 1994](https://pubmed.ncbi.nlm.nih.gov/7932200/)). - **GABA-A receptors, biphasically:** At low concentrations nefiracetam increases currents through GABA-A receptors (the main brake on brain activity, where GABA is gamma-aminobutyric acid, the principal calming neurotransmitter); at higher concentrations it suppresses them ([Huang et al., 1996](https://pubmed.ncbi.nlm.nih.gov/9014140/)). This dual action is the likely source of the "calm focus" description common in user reports. - **Growth factor signalling:** In rats with brain emboli (small clots lodged in brain blood vessels), nefiracetam raised hippocampal brain-derived neurotrophic factor (BDNF, a protein that keeps neurons alive and supports the growth of new connections) and synapsin I ([Ando et al., 2005](https://pubmed.ncbi.nlm.nih.gov/15659294/)). **Competing mechanistic accounts.** Two explanations compete for primacy. The Northwestern and Tohoku groups argue that nicotinic receptor potentiation is the initiating event and the intracellular kinase cascade is downstream. The calcium-channel account, developed largely by Yoshii and colleagues, holds that direct prolongation of calcium channel opening through a protein kinase A (PKA, an enzyme switched on by a universal chemical messenger that cells use to relay signals from their surface inward) pathway is primary and independent of the synapse. Examine's assessment treats both as real but non-overlapping, with the calcium pathway carrying long-term potentiation and the kinase pathway carrying signal amplification. A third, sceptical reading is also on the table: the potentiation is bell-shaped and peaks at roughly 10 nM, about 170% of control, and falls away at higher concentrations ([Moriguchi, 2011](https://pubmed.ncbi.nlm.nih.gov/21821968/)). Under this reading, the concentrations achieved by oral dosing may sit past the peak of the curve, which would explain why an elegant laboratory profile produced repeatedly disappointing clinical results. **Key pharmacological properties.** Nefiracetam is fat-soluble and reaches maximum blood concentrations within two hours of an oral dose, with a half-life of 3–5 hours and linear kinetics from 10 mg to 200 mg. Fewer than 10% of the dose leaves in urine unchanged and less than 0.1% in stool, so clearance is almost entirely metabolic ([Fujimaki et al., 1992](https://pubmed.ncbi.nlm.nih.gov/1360528/)). Three main metabolites circulate with substantially longer half-lives of 7.8–21.9 hours, and steady state across parent compound and metabolites is reached after about seven days of three-times-daily dosing ([Fujimaki et al., 1993](https://pubmed.ncbi.nlm.nih.gov/8484264/)). The principal human metabolic route is 5-hydroxylation by CYP3A4 (an enzyme in the cytochrome P450 family that is the liver's main workhorse for clearing drugs), with minor contributions from other family members ([Fujimaki et al., 1996](https://pubmed.ncbi.nlm.nih.gov/8879146/)). Its selectivity is low by modern standards: it touches the acetylcholine, glutamate, GABA, and monoamine (dopamine, noradrenaline, and serotonin) systems as well as calcium channels, and tissue distribution is broad rather than brain-selective, which is directly relevant to the kidney, bladder, and testicular findings described below. ## Historical Context & Evolution - **Original intended use:** Nefiracetam was synthesised by Daiichi Pharmaceutical (later Daiichi Sankyo) in Japan under the code DM-9384 as an antidementia drug. The target indication was cognitive and behavioural impairment following cerebral infarction (a stroke caused by a blocked artery in the brain), with Alzheimer's-type dementia as a second programme. It was never conceived as a healthy-brain enhancer ([Tanaka et al., 1994](https://pubmed.ncbi.nlm.nih.gov/8018089/)). - **What the early research actually found:** The preclinical package was unusually broad and unusually positive. Nefiracetam reversed memory impairment caused by scopolamine, cycloheximide, ethanol, and benzodiazepines (a class of sedative and anti-anxiety medicines) in rodents ([Hiramatsu et al., 1997](https://pubmed.ncbi.nlm.nih.gov/9062668/)); improved water-maze performance after traumatic brain injury in rats ([DeFord et al., 2001](https://pubmed.ncbi.nlm.nih.gov/11509223/)); and, in older rabbits given only fifteen daily injections at 10 mg/kg, improved relearning of a conditioned response that was still measurable five weeks after dosing stopped ([Woodruff-Pak et al., 2002](https://pubmed.ncbi.nlm.nih.gov/12385816/)). It also protected retinal neurons from death caused by ischemia (an interrupted blood supply), both in cell culture and in living animals ([Ueda et al., 2004](https://pubmed.ncbi.nlm.nih.gov/14718588/)). These are real findings that were never overturned; what happened instead is that they did not reproduce in people. - **The clinical programme and its end:** Phase III trials ran in Japan, phase II trials (the smaller, earlier stage that tests whether a drug works at all) in the United States for post-stroke symptoms and Alzheimer's-type dementia, and a full programme completed in China in preparation for a filing. Japanese phase III trials were redesigned and repeated. In February 2002 Daiichi withdrew its Japanese marketing application, citing insufficient efficacy in the revised trial ([Crespi, 2002](https://pubmed.ncbi.nlm.nih.gov/12090554/)). A National Institute of Neurological Disorders and Stroke phase II trial in 50 Alzheimer's patients completed the month before, in January 2002, and never reported results ([NCT00001933](https://clinicaltrials.gov/study/NCT00001933)). - **How the picture changed, and in which direction:** The shift was not from "it works" to "it was debunked". The animal pharmacology stands; the mechanistic work continued to deepen for another decade after commercial development stopped. What changed is that the only adequately sized human trial in stroke survivors missed its primary endpoint: the 159-patient depression trial did not separate from placebo ([Robinson et al., 2008](https://pubmed.ncbi.nlm.nih.gov/18451188/)), and the positive apathy result reported from the 137 patients of that same trial who completed at least four weeks of treatment therefore stands as a subgroup finding rather than an independent replication ([Robinson et al., 2009](https://pubmed.ncbi.nlm.nih.gov/19622685/)). A later attempt to confirm that apathy signal recruited only 13 patients from 2,514 screened and was uninterpretable ([Starkstein et al., 2016](https://pubmed.ncbi.nlm.nih.gov/26915605/)). New evidence arriving on the negative side was thin as well as negative — the case against nefiracetam rests substantially on trials that were too small or too poorly targeted to settle the question either way. - **Structural incentives shaping what got studied:** Once the marketing application was withdrawn, the patent estate lost its value and no party had a commercial reason to fund further trials. The competing treatments in the same clinical space — donepezil, escitalopram, galantamine — are inexpensive generics that insurers and national health systems already cover, so payers have no incentive to fund comparative research into an unapproved compound that would need a new regulatory dossier. The result is not that nefiracetam was tested and failed cleanly; it is that testing stopped when the money did. - **How it re-entered use:** With no regulatory owner and an expired commercial interest, nefiracetam moved into the grey market for cognitive enhancers, where it is sold as a research chemical and discussed largely on the strength of the animal literature and the 2009 apathy result. ## Expected Benefits Benefits below are graded by how strong the human evidence is, not by how large the claimed effect is. For a longevity-oriented reader the practical consequence is stark: nothing here has been tested in a healthy adult. ### High 🟩 🟩 🟩 No benefit of nefiracetam is supported at this evidence level. No meta-analysis favours it for any outcome, and no adequately powered randomized controlled trial (RCT, a study in which participants are randomly assigned to receive the treatment or an inactive comparator) has met its primary endpoint. ### Medium 🟩 🟩 #### Reduction of Apathy After Stroke in People Who Are Also Depressed ⚠️ Conflicted Apathy — the loss of drive, initiative, and interest, distinct from low mood — affects roughly a third of stroke survivors. In a multicentre phase II RCT, 70 of 137 patients with post-stroke major depression also met criteria for apathy and were randomized to placebo, 600 mg, or 900 mg of nefiracetam daily. The 900 mg arm showed a significantly greater improvement in Apathy Scale scores than either 600 mg or placebo, with a significant time-by-treatment interaction (the groups improved at significantly different rates over the course of the trial). The proposed mechanism is amplification of cholinergic and dopaminergic transmission in the frontal-subcortical circuits that generate goal-directed behaviour. The finding is flagged as conflicted because a later two-centre RCT designed specifically to confirm it randomized only 13 patients and found no between-group difference, and because the 2025 systematic review concluded the benefit appears only where depression coexists. **Magnitude:** In the 70-patient apathy subgroup, 900 mg/day produced a significantly greater fall in Apathy Scale score than 600 mg/day or placebo over at least four weeks of treatment. In the 13-patient confirmatory trial, Apathy Scale scores fell by a mean of 7.0 points across both arms (95% confidence interval, the range within which the true value most likely lies, −14.6 to 0.6), with no significant difference between nefiracetam and placebo at 12 weeks. ### Low 🟩 #### Cognitive Improvement in Vascular Cognitive Impairment ⚠️ Conflicted This was the indication nefiracetam was built for: memory and executive impairment following cerebral infarction. Early Japanese phase II work at 600–900 mg/day over 8–12 weeks reported improvement on standard dementia rating scales, which is what carried the compound into Japanese phase III testing and into trial programmes in the United States and China. The proposed mechanism is restoration of cholinergic tone plus enhanced synaptic plasticity in surviving tissue around the infarct. The evidence is flagged as conflicted because the redesigned Japanese phase III trial did not reproduce a clinically meaningful effect, the marketing application was withdrawn on that basis, and the parallel Alzheimer's trial never reported a result — so the positive and negative datasets are of similar vintage and neither has been fully published in a form that permits independent appraisal. **Magnitude:** Not quantified in available studies. #### Improvement of Mood in Severe Post-Stroke Depression ⚠️ Conflicted Nefiracetam entered depression research because preliminary work suggested it increased cerebral blood flow and improved outlook and energy after stroke. In a 159-patient double-blind trial it did not separate from placebo overall, but among patients in the top fifth of baseline depression severity, 900 mg/day produced a significant improvement over 600 mg/day and placebo. The mechanism is presumed to run through the monoamine and acetylcholine systems rather than through serotonin, which would make it unlike conventional antidepressants. It is flagged as conflicted because the network meta-analysis that pooled it against nine other agents ranked it last. **Magnitude:** In the 159-patient trial, response rates exceeded 70% and remission rates exceeded 40% in both nefiracetam and placebo arms, with a significant drug effect confined to the most severely depressed quintile at 900 mg/day. In the network meta-analysis of 12 trials and 707 participants, nefiracetam's standardized mean difference (SMD, a measure expressing an effect in units of the spread of the data) against placebo was 0.51 in the direction favouring placebo, compared with −6.54 for the best-performing agent. ### Speculative 🟨 #### Memory and Learning Enhancement in Cognitively Healthy Adults This is the reason most people in a longevity context take nefiracetam, and it is the claim with the least support. No controlled trial has ever enrolled cognitively healthy volunteers. The basis is entirely mechanistic — potentiation of nicotinic and glutamate receptors and enhanced long-term potentiation in slice preparations — combined with animal work in which the animals were impaired to begin with, plus uncontrolled self-report. The bell-shaped concentration–response curve raises the specific possibility that a brain with normal cholinergic tone gains nothing, or is pushed past the optimum. #### Enhancement of Synaptic Plasticity and Neurogenesis Prolonged daily dosing, though not a single dose, has been reported to raise the brain's capacity to remodel its own connections and to form new nerve cells (neurogenesis, the generation of new neurons in the adult brain). In rats dosed continuously, the resting number of newly formed nerve cells in the hippocampus that are still able to migrate and wire in rose to the level seen in animals reared in an enriched, stimulating environment, and the size of that shift tracked directly with how well the animals learned a spatial task ([Murphy et al., 2006](https://pubmed.ncbi.nlm.nih.gov/15988469/)). The proposed mechanism is sustained cholinergic drive rather than anything unique to nefiracetam, since two unrelated cholinergic drugs produced the same change in the same experiment. No human study has measured plasticity or new nerve cell formation on this compound, so the basis is preclinical and mechanistic only. #### Neuroprotection After Ischemia or Head Injury In rats subjected to blocked brain blood vessels or controlled head injury, nefiracetam improved subsequent spatial learning and raised hippocampal growth factor levels; in models of interrupted blood supply to the retina it reduced both uncontrolled cell death and the orderly self-destruction programme cells run when damaged. No human neuroprotection endpoint has been tested. The basis is preclinical and mechanistic only. #### Elevation of Seizure Threshold Nefiracetam suppressed electroshock-induced seizures at non-toxic doses in mice and rats with a safety margin superior to several licensed anticonvulsants, and shortened both the abnormal electrical discharges and the behavioural seizures of rats in which epilepsy had been established by repeated electrical stimulation ([Kitano et al., 2005](https://pubmed.ncbi.nlm.nih.gov/15946322/); [Kitano et al., 2005](https://pubmed.ncbi.nlm.nih.gov/16190926/)). It had no effect on chemically induced seizures and did not slow the process by which that epilepsy was established in the first place. No human anticonvulsant trial was conducted, so the basis is animal data only. #### Relief of Neuropathic Pain A single line of work in mice found a non-opioid analgesic action specific to neuropathic rather than inflammatory pain ([Rashid & Ueda, 2002](https://pubmed.ncbi.nlm.nih.gov/12235255/)). This has not been replicated in another species or examined in humans; the basis is a single preclinical programme. #### Preservation of Age-Related Learning Capacity Older rabbits given fifteen daily doses relearned a conditioned eyeblink response better than controls, and the advantage persisted five weeks after the last dose — a persistence pattern that would be relevant if it held in humans. The evidence is from one laboratory in one species with no controlled human counterpart, so it remains mechanistic and anecdotal in the human context. ## Benefit-Modifying Factors - **Concentration sits on a bell-shaped curve:** This is the single most consequential modifier. Potentiation of glutamate receptor currents and of long-term potentiation peaks at roughly 10 nM and declines at higher concentrations. Anyone dosing upward in search of a stronger effect may be moving away from the optimum rather than toward it, and the clinical trial doses of 600–900 mg/day may already have overshot it. - **Baseline cholinergic deficit:** Every positive animal result involved an artificially or pathologically impaired system — scopolamine blockade, embolic injury, ageing. Where cholinergic transmission is already intact, there is less headroom for a positive modulator to work in, which is a plausible reason why healthy-adult benefit has never been demonstrated. - **Baseline symptom severity as a biomarker:** In both human trials the drug effect appeared only in the most affected subgroups — the top quintile of depression severity, and the patients who met formal apathy criteria. Baseline Apathy Scale and depression rating scores therefore function as the practical predictors of response, and there is no evidence of benefit at low baseline symptom burden. - **CYP3A4 activity and genetic variation in it:** Because 5-hydroxylation by CYP3A4 is the main clearance route, anything that changes CYP3A4 throughput changes exposure. The CYP3A5*3 variant, which leaves most carriers of European descent without functional CYP3A5 enzyme, and normal variation in CYP3A4 expression can shift blood levels several-fold between individuals at the same oral dose. Given the bell-shaped curve, this cuts both ways. - **Pre-existing cerebrovascular disease:** The only human populations ever studied had recent stroke. Whether the presence of blood-starved brain tissue is necessary for benefit, or merely the context in which it was looked for, is unresolved. - **Sex-based differences:** No sex-stratified efficacy analysis has been published for either human trial, and both enrolled men and women. The animal efficacy work used males predominantly. There is therefore no evidence that benefit differs by sex — which is a gap, not a reassurance, and it stands in contrast to the clearly male-specific toxicity described below. - **Age within the target range:** The rabbit and rodent work that showed the largest effects used aged animals, and the human trials enrolled a mean age near 67. For a healthy adult in their forties there is no directly applicable data, and the mechanistic argument for benefit is weaker where age-related cholinergic decline has not yet begun. ## Potential Risks & Side Effects Risk grades below describe how well established each finding is, not how likely it is to occur at any given dose. The two High-grade items are established in animals; their human relevance is explicitly unknown. ### High 🟥 🟥 🟥 #### Testicular Atrophy and Impaired Sperm Production in Animals Nefiracetam damages the testis in two species by the same route. In beagle dogs, testicular testosterone fell within four hours of a single high dose, serum testosterone fell after single and repeated dosing while estradiol rose, and by four weeks the seminiferous tubules (the coiled tubes inside the testis where sperm are manufactured) showed moderate to severe atrophy with abnormal fused cells, accompanied by reduced sperm motility and increased malformed sperm. Luteinizing hormone (LH, the pituitary signal that tells the testis to make testosterone) and follicle-stimulating hormone (FSH, the pituitary signal that drives sperm production) were unchanged throughout, locating the fault in the Leydig cells (the testicular cells that manufacture testosterone) and their conversion of progesterone to testosterone, rather than in the pituitary gland. Rats showed the identical progression at higher doses, with an extremely low fertility index ([Shimada et al., 2003](https://pubmed.ncbi.nlm.nih.gov/12849691/); [Harada et al., 1995](https://pubmed.ncbi.nlm.nih.gov/8667455/)). No human reproductive endpoint has ever been measured, but the finding was taken seriously enough that the National Institutes of Health Alzheimer's trial excluded any man interested in conceiving children, citing potential adverse effects on sperm production. **Magnitude:** Seminiferous atrophy appeared in dogs at 180 mg/kg/day and was severe at 300 mg/kg/day after four weeks; in rats, spermatid retention and reduced sperm head counts appeared at 500 mg/kg/day and full tubular atrophy at 1500 mg/kg/day. A 900 mg daily human dose is about 13 mg/kg in a 70 kg adult, so the lowest dog dose producing atrophy is roughly 14-fold higher on a milligram-per-kilogram basis; correcting for body surface area narrows that margin to roughly 8-fold. #### Renal Papillary Necrosis and Bladder Injury in Dogs Renal papillary necrosis (death of the innermost tip of the kidney, where urine is concentrated before it drains away) was the defining canine lesion. At 300 mg/kg/day, dogs developed degeneration and shedding of bladder lining cells with swelling and bleeding in the underlying tissue from the first week, presenting clinically as blood and protein in the urine. The bladder then regenerated, but the kidney did not: by week 11 the kidney tip and its drainage ducts showed degeneration and abnormal overgrowth of their lining cells with bleeding into the surrounding tissue, and one male and two female dogs died in weeks 10–11 with extensive haemorrhage and tissue death at the papilla ([Kashida et al., 1996](https://pubmed.ncbi.nlm.nih.gov/8923675/)). A follow-up study identified the lining cell of the papillary duct as the primary target and showed the lesion develops by a route distinct from that of anti-inflammatory drugs, with rising urine volume and falling urine concentration as the earliest detectable signs ([Tsuchiya et al., 2005](https://pubmed.ncbi.nlm.nih.gov/16105799/)). The finding is species-specific as far as anyone has tested; rats and monkeys did not reproduce it. **Magnitude:** Fatal papillary necrosis in 3 of the dogs dosed at 300 mg/kg/day for 11 weeks, roughly 23-fold the milligram-per-kilogram equivalent of a 900 mg human daily dose. Bladder lesions appeared within one week at the same dose. ### Medium 🟥 🟥 #### Gastrointestinal Upset and Nausea Mild digestive complaints are the most consistently reported adverse events in the human trials, which is unsurprising for an oral compound taken three times daily. No mechanism specific to nefiracetam has been proposed; the pattern resembles that of other racetams (the family of piracetam-derived compounds to which nefiracetam belongs). Severity was mild and the events were reversible on stopping. The grade reflects that this is one of the few adverse effects actually observed in humans under controlled conditions rather than inferred from animals. **Magnitude:** In the network meta-analysis of 12 post-stroke depression trials with 707 participants, all-cause discontinuation on nefiracetam did not differ significantly from placebo. Published tolerability summaries place gastrointestinal events in fewer than 5% of participants. #### Mislabelled, Adulterated, or Misdosed Product Because no regulated nefiracetam product exists, every unit consumed comes from an unregulated supply chain. Analytical surveys of the cognitive-enhancement supplement market have repeatedly found undeclared unapproved drugs, declared drugs absent, and quantities well off label. The mechanism of harm is straightforward: an unintended compound or an unintended dose. This matters more for nefiracetam than for a typical supplement because the compound has a narrow effective concentration window and a documented organ toxicity at multiples of the intended dose. **Magnitude:** In an analysis of 10 cognitive-enhancement products, five unapproved drugs were detected, 9 of 12 declared quantities were inaccurate, and consumers could be exposed to up to four times a pharmaceutical dose and as many as four unapproved drugs from a single product ([Cohen et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34484905/)). A 12-laboratory European and Australian surveillance study documented 159 samples containing 34 distinct nootropic molecules, 69% of them from the illegal market and 49% presented as dietary supplements ([Vanhee et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40558871/)). ### Low 🟥 #### Headache, Fatigue, Nervousness, and Anxiety Practitioner and user reports describe headache, tiredness, nervousness, anxiety, and nausea, typically at the upper end of the dose range. The proposed mechanism is twofold: acetylcholine turnover accelerated beyond the available choline supply, which is the standard explanation for racetam headache, and the loss of GABA-A potentiation at higher concentrations, which would remove the calming component and leave the excitatory one. These are not controlled observations, and the grade reflects that. **Magnitude:** Not quantified in available studies. #### Suppression of Circulating Testosterone Separately from structural testicular damage, nefiracetam lowered circulating testosterone rapidly and reversibly in both dogs and rats after a single dose, with recovery within a day, and raised estradiol in dogs over weeks of dosing. For a longevity-oriented adult, a sustained downward shift in testosterone with an upward shift in estradiol would be an unwelcome trade even in the absence of structural injury. Whether this occurs at human doses is unmeasured; the grade reflects consistent animal data at doses far above human use with no human confirmation. **Magnitude:** In dogs at 300 mg/kg/day, testicular testosterone fell within four hours of a single dose and serum testosterone was depressed after single, one-week, and two-week dosing, while serum estradiol rose from week 1 to week 4. In rats, both serum and testicular testosterone fell after a single dose and recovered within 24 hours. ### Speculative 🟨 #### Excitatory Overshoot at High Doses ⚠️ Conflicted The concern is theoretical and arises directly from the mechanism: a compound that potentiates NMDA receptors, prolongs calcium channel opening, and suppresses GABA-A currents at higher concentrations has, on paper, the ingredients for excitotoxicity (damage caused by over-stimulating neurons to death). The evidence runs the other way — nefiracetam suppressed seizures in electroshock models with a safety margin better than several licensed drugs, suppressed the silent seizures that follow interrupted blood flow in rats, and reduced seizure severity in rats with established epilepsy. No human seizure has been attributed to it. The conflict is between mechanistic plausibility and consistently reassuring animal data, with no human data to arbitrate. #### Accumulation Through Liver Enzyme Interaction Because clearance runs almost entirely through CYP3A4 and the metabolites persist far longer than the parent compound, a strong CYP3A4 inhibitor taken concurrently could raise exposure substantially. This has not been formally studied in humans, but the National Institutes of Health trial protocol treated it as a real hazard and excluded CYP3A4 inhibitors entirely. The basis is pharmacokinetic inference plus that protocol decision, not observed events. #### Sleep Disruption Reports of difficulty falling asleep when dosing late in the day are common in user accounts and are mechanistically plausible given nicotinic receptor potentiation and increased monoamine turnover. No sleep study has been performed. The basis is anecdotal and mechanistic only. ## Risk-Modifying Factors - **Male sex and reproductive intent:** The dominant toxicity is male-specific. Men who intend to conceive, or who already have marginal semen parameters, carry a categorically different risk profile from women or from men past reproductive planning. This was the one exclusion the National Institutes of Health trial wrote explicitly into its protocol. - **Baseline testosterone and semen quality:** A man starting with low-normal total testosterone or borderline sperm concentration has less reserve before an animal-suggested downward shift would become clinically meaningful. These are the biomarkers that convert an abstract animal finding into a measurable personal risk. - **Baseline kidney function and urine concentrating ability:** The canine kidney lesion announced itself through rising urine volume and falling urine concentration before any structural change was visible. Anyone with reduced estimated glomerular filtration rate (eGFR, a calculated measure of how fast the kidneys filter blood), existing papillary disease, chronic dehydration, or long-term non-steroidal anti-inflammatory drug use starts closer to that threshold. - **CYP3A4 genotype and phenotype:** Poor CYP3A4 throughput, whether from genetic variation, liver disease, or co-administered inhibitors, raises exposure at any given dose and moves the individual toward the doses where animal toxicity was observed. - **Pre-existing liver impairment:** With clearance almost entirely metabolic and negligible renal or faecal elimination of unchanged drug, hepatic insufficiency has an outsized effect on exposure. The Alzheimer's trial excluded anyone whose transaminases (liver enzymes that leak into the blood when liver cells are stressed) exceeded three times the upper limit of normal, or whose bilirubin exceeded 2.0 mg/dL. - **Seizure history:** The Alzheimer's trial excluded current seizure disorder and prohibited anticonvulsants, despite nefiracetam's anticonvulsant profile in animals — a conservative stance that reflects how little was known about interaction with antiepileptic regimens. - **Age at the older end of the range:** Older adults have lower CYP3A4 capacity, reduced renal concentrating ability, and lower baseline testosterone, so all three risk channels widen simultaneously. They are also the group in whom any benefit is most plausible, which makes the trade-off sharper rather than simpler. ## Key Interactions & Contraindications - **Strong CYP3A4 inhibitors (ketoconazole, itraconazole, fluconazole, miconazole, clarithromycin, erythromycin, troleandomycin, ritonavir, grapefruit juice):** Severity — avoid. These were absolute exclusions in the National Institutes of Health trial protocol. Consequence: reduced clearance and raised exposure toward the concentration range associated with organ toxicity in animals. Mitigation: separation by at least two weeks, as the trial protocol required, or no concurrent use at all. - **CYP3A4 inducers (rifampicin, carbamazepine, phenytoin, *Hypericum perforatum* / St. John's wort, modafinil):** Severity — caution. Consequence: accelerated clearance and loss of any effect, without a reliable way to detect it since there is no therapeutic drug monitoring for this compound. Mitigation: none reliable — dose escalation to compensate reintroduces uncertainty about which concentration is actually reached. - **Cholinesterase inhibitors (donepezil, rivastigmine, galantamine — drugs that slow the breakdown of acetylcholine so that more of it remains available):** Severity — caution, monitor. Consequence: additive cholinergic load producing nausea, cramping, slowed heart rate, and vivid dreams. Nefiracetam and galantamine act on the same nicotinic receptors by complementary routes, so the combination is genuinely additive rather than merely coincidental. Mitigation: staggered rather than simultaneous initiation, with at least four weeks between the two starts. - **Anticholinergic medications (oxybutynin, tolterodine, diphenhydramine, amitriptyline, scopolamine — drugs that block acetylcholine's action):** Severity — caution. Consequence: direct pharmacological opposition — scopolamine blockade is the standard model nefiracetam was shown to reverse, so co-administration is expected to null the intended effect while retaining the risk. Mitigation: none available beyond avoiding the combination. - **Anticonvulsants (carbamazepine, phenytoin, valproate, levetiracetam) and psychostimulants (methylphenidate, amphetamine, modafinil):** Severity — caution. Consequence: unknown; these were prohibited within two weeks of enrolment in the Alzheimer's trial because no interaction data existed and none has been generated since. Mitigation: none; the interaction is uncharacterised. - **Sedatives acting on GABA (benzodiazepines, zolpidem, alcohol, phenibut):** Severity — caution. Consequence: unpredictable rather than simply additive, because nefiracetam's effect on GABA-A receptors reverses direction with concentration — potentiating at low levels and suppressing at higher ones. Mitigation: none beyond avoidance of the combination, particularly at the upper end of the nefiracetam dose range. - **Nicotine and other compounds that activate the same receptors (varenicline, cytisine):** Severity — monitor. Consequence: nefiracetam amplifies signalling through the same α4β2 receptors nicotine activates, so the practical effect of a given nicotine dose may be larger than expected. Mitigation: reduction of the nicotine dose rather than the nefiracetam dose where overstimulation appears. - **Choline donors (alpha-glycerylphosphorylcholine (alpha-GPC), citicoline, choline bitartrate):** Severity — additive, generally intentional. Consequence: increased acetylcholine availability. Standard community practice pairs nefiracetam with 250–300 mg citicoline specifically to prevent the headache attributed to acetylcholine depletion, and this is the most commonly described deliberate combination. Excess choline produces its own headache and gastrointestinal upset, so the additive relationship is not monotonic. - **Other racetams and cholinergic supplements (piracetam, aniracetam, huperzine A, acetyl-L-carnitine):** Severity — caution. Consequence: additive cholinergic effects with no dose–response data for any combination, and cumulative uncertainty rather than cumulative benefit. Mitigation: single-agent use for any period in which effects are being assessed. - **CYP3A4-inhibiting supplements (berberine, bergamot, high-dose quercetin, black pepper extract):** Severity — caution. Consequence: the same exposure increase as pharmaceutical inhibitors, but without any of the labelling that would flag it. Mitigation: the same dose-timing separation that applies to pharmacological inhibitors. **Populations for whom nefiracetam is contraindicated:** - **Men actively pursuing conception, or with sperm concentration below 15 million/mL, motility below 40%, or normal forms below 4%:** absolute contraindication, on the basis of replicated testicular toxicity in two species and the exclusion written into the only National Institutes of Health protocol. - **Chronic kidney disease of stage 3 or worse (eGFR below 60 mL/min/1.73 m²), a history of renal papillary necrosis, or analgesic nephropathy (kidney damage caused by years of heavy painkiller use):** absolute contraindication, given the canine papillary lesion. - **Moderate to severe hepatic impairment (Child-Pugh Class B or C, the standard grading of liver failure severity), or transaminases above three times the upper limit of normal:** absolute contraindication, given exclusively hepatic clearance. - **Pregnancy and lactation:** absolute contraindication. Rat fetuses at 1000 mg/kg/day showed reduced body weight, delayed bone formation, and increased skeletal variations, and rabbit fetuses showed increased skeletal variations at 270 mg/kg/day, although no birth defects were produced at any dose ([Watanabe et al., 1994](https://pubmed.ncbi.nlm.nih.gov/8018096/)). - **Anyone under 18, and anyone with an active seizure disorder:** avoid; both were exclusions in the clinical programme and neither has been studied. ## Risk Mitigation Strategies - **Dose ceiling well below the clinical trial range:** The animal toxicity margin is calculated from the 900 mg/day figure, and a 150–450 mg/day range in three divided doses — the range Examine describes for supplemental use — roughly triples the separation from the lowest dose that atrophied dog testes. This directly mitigates the testicular and renal findings, and costs little given that the concentration–response curve peaks at nanomolar levels anyway. - **Pre-treatment reproductive baseline in men:** A semen analysis plus total testosterone, free testosterone, LH, FSH, and sensitive estradiol before the first dose converts the primary animal risk into something measurable. Without a pre-treatment value, a later abnormal result cannot be attributed to anything. This mitigates the risk of an undetected, potentially prolonged decline in fertility. - **Repeat reproductive markers at 12 weeks and every 6 months thereafter:** In dogs, hormonal change preceded structural change by roughly four weeks, and structural change preceded measurable semen abnormality. Serum testosterone is the earliest sensitive parameter identified in the dog work, which makes it the practical early-warning marker for the testicular lesion. - **Urine volume and first-morning urine concentration tracking:** Rising urine volume and falling urine concentration were the earliest laboratory signals of the canine kidney lesion, appearing before structural damage. A first-morning urine osmolality above 600 mOsm/kg every 6 months, together with a dipstick check for blood and protein, mitigates the renal papillary risk at negligible cost. - **Generous fluid intake and avoidance of concurrent non-steroidal anti-inflammatory drugs:** The renal papilla is the most poorly perfused region of the kidney and is the shared target of nefiracetam and analgesic nephropathy. Sustained hydration and avoiding chronic ibuprofen, naproxen, or diclofenac use mitigates additive papillary injury. - **Batch certificate of analysis and, where possible, independent testing for every product:** Given that roughly three-quarters of declared quantities in analysed cognitive-enhancement products were inaccurate, a batch-specific certificate showing identity and purity by high-performance liquid chromatography (HPLC, a laboratory method that separates and quantifies the components of a mixture) mitigates the adulteration and misdosing risk that no other strategy addresses. - **Choline donor pairing from the first dose:** 250–300 mg of citicoline alongside each nefiracetam dose is the standard mitigation for the headache and irritability attributed to accelerated acetylcholine turnover outstripping choline supply. - **Introduction as a single new variable held for at least four weeks:** Because nefiracetam does not act acutely and steady state across parent compound and metabolites takes about seven days, changing anything else in the same window makes both benefit and adverse effects unattributable. This mitigates the risk of continuing a compound with a real toxicity profile on the strength of an effect that came from somewhere else. - **Stop rule defined before the first dose:** Predefined thresholds — a fall in total testosterone below 400 ng/dL, any new blood or protein in urine, eGFR falling below 75 mL/min/1.73 m², or any measurable decline in semen parameters — convert monitoring into action and mitigate the risk of drifting past an early signal. ## Therapeutic Protocol There is no approved prescribing information for nefiracetam anywhere in the world, so no protocol carries regulatory authority. Two distinct approaches exist, and they differ by a factor of about four in daily dose. - **The clinical trial protocol:** 600 mg or 900 mg per day, given as three divided doses, for 9 to 12 weeks. This is the regimen Daiichi Pharmaceutical used across its Japanese programme and that Robinson and Starkstein used in the post-stroke trials; the National Institutes of Health Alzheimer's trial used three tablets twice daily for 20 weeks. It is the only dose range with controlled human efficacy and safety data behind it, and it is also the range from which the animal toxicity safety margins are calculated. - **The supplemental protocol:** 150–450 mg per day in three divided doses, which is the range Examine's assessment describes as reflecting actual supplemental use; the practitioner literature, principally David Tomen's write-up, gives a wider 100–900 mg per day in two divided doses, morning and early afternoon. This approach is not derived from trials; it back-calculates from the 3–10 mg/kg animal doses that produced most behavioural effects, which scale to roughly 0.5–1.6 mg/kg in humans, or 35–110 mg for a 70 kg adult. Neither approach stands as the default: the trial dose has data but a thinner safety margin, the lower dose has a wider margin but no efficacy evidence at all. - **Time of day:** Morning and early afternoon. With a 3–5 hour half-life the parent compound is largely cleared before evening, but nicotinic potentiation and increased monoamine turnover make late dosing a plausible cause of delayed sleep onset. The trial regimens divided doses across the waking day rather than concentrating them. - **Half-life and dose splitting:** The parent compound's half-life of 3–5 hours is short relative to a daily dosing interval, which is why every trial regimen split the dose two or three ways rather than giving it once. The three main metabolites persist far longer, at 7.8–21.9 hours, so total exposure accumulates for about a week before plateauing even though the parent compound does not. - **Onset requires repeated dosing:** A single dose does not measurably affect memory formation. Effects in animals and the limited human data appear only after seven or more days of daily dosing, which makes single-dose experimentation uninformative. - **Genetic factors in dose selection:** CYP3A4 and CYP3A5 activity is the main pharmacogenetic lever. Carriers of two non-functional CYP3A5*3 alleles — the majority of people of European descent — clear CYP3A substrates more slowly than CYP3A5 expressers, which argues for starting at the low end. APOE4 status (a gene variant that raises Alzheimer's risk and alters cholinergic signalling) has not been examined in relation to nefiracetam response despite the compound's cholinergic mechanism, and is an obvious untested modifier. - **Sex-based differences in dosing:** No sex-specific dosing has been established, and neither human trial published a sex-stratified analysis. The asymmetry runs in the safety direction rather than the efficacy direction: the defining animal toxicity is testicular, so the risk calculus differs by sex even where the dose does not. - **Age-related considerations:** CYP3A4 capacity declines with age, so identical doses produce higher exposure in older adults. The human trials enrolled a population with a mean age near 67 at 600–900 mg/day without dose adjustment, but for anyone at the older end of the range starting at the low end of the supplemental range is the more conservative reading of the same data. - **Baseline biomarkers influencing response:** Baseline apathy and depression severity were the only measured predictors of response in the human data. Baseline testosterone, kidney function, and liver enzymes influence tolerability rather than response, and belong in the pre-dose workup regardless. - **Pre-existing conditions influencing response:** Every human efficacy signal came from people with recent cerebrovascular injury. Whether an intact brain responds at all is untested, and this is the largest single gap between the protocol as studied and the protocol as used. - **Choline co-administration:** Standard community practice pairs each dose with 250–300 mg citicoline and, in some protocols, acetyl-L-carnitine. This is not a trial-derived component; it originates in the nootropic practitioner literature and is applied across the racetam class generally. ## Discontinuation & Cycling - **Intended duration:** Nefiracetam was developed as a chronic therapy for a chronic condition, and the trials ran 9 to 20 weeks with an optional seven-month extension in the Alzheimer's protocol. No human dataset extends beyond that, so anything longer than about five months is outside all available evidence. The animal toxicity findings emerged between weeks 4 and 11 of continuous high-dose exposure, which makes indefinite uninterrupted use the least evidence-supported pattern of all. - **Withdrawal effects:** None documented. A formal dependence study in rats using both drug-admixed food and intravenous self-administration found no withdrawal signs after 43 days of escalating exposure and no reinforcement liability, with self-administration frequency at or below saline controls ([Fujikawa et al., 1994](https://pubmed.ncbi.nlm.nih.gov/8018097/)). No human withdrawal syndrome has been reported. - **Tapering:** Not required on current evidence. With no physical dependence in animals, no reported human withdrawal, and a short parent half-life, abrupt cessation has no established hazard. The practical argument for a taper is different: stopping gradually makes it easier to identify which effects were drug-attributable. - **Cycling:** No efficacy-based case for cycling exists, because tolerance has not been demonstrated — the older-rabbit work found the effect persisted five weeks after dosing stopped, which is the opposite of a tolerance pattern. The case for cycling is a safety case. Since the animal organ toxicity is a function of continuous exposure duration, scheduled off-periods — for instance eight to twelve weeks on followed by four weeks off — limit cumulative exposure and provide a clean window for repeat biomarker testing against a drug-free baseline. - **What discontinuation looks like in practice:** Because effects require a week or more of dosing to appear, they fade over a comparable or longer period rather than immediately, and the rabbit data suggest some learning-related effects may outlast the drug entirely. A meaningful assessment of what the compound was contributing therefore needs at least four weeks off, not a few days. ## Sourcing and Quality - **No pharmaceutical-grade source exists:** Nefiracetam is not approved in any jurisdiction and no licensed manufacturer produces a finished product. Every available unit comes from a bulk chemical supplier selling material designated for laboratory use, and there is no compounding pharmacy route because there is no prescription to compound against. This is the defining sourcing fact and it has no workaround. - **Certificate of analysis, batch-matched:** The single most useful quality signal is a certificate of analysis tied to the specific lot number on the container, showing identity by mass spectrometry or nuclear magnetic resonance and purity by high-performance liquid chromatography. A generic certificate not tied to a lot, or one dated years before the batch, carries no information. - **Independent third-party testing:** Because the supplier commissioning its own certificate has an obvious interest in the result, the meaningful check is a test commissioned separately from the seller. Analytical laboratories that serve the supplement sector will run identity and purity panels on a submitted sample; for a compound with a documented organ toxicity profile, this is proportionate rather than excessive. - **What contamination looks like in this category:** Market surveillance found undeclared unapproved drugs in cognitive-enhancement products, declared ingredients absent, and quantities inaccurate in three-quarters of cases, with phenibut, vinpocetine, and picamilon appearing in products that did not list them. Residual solvents and heavy metals from bulk synthesis are the other realistic contaminants, and neither is visible on inspection. - **Formulation and physical form:** Nefiracetam is poorly water-soluble, which is why formulation science has focused on improving its dissolution — thirteen cocrystal forms (crystals in which the compound is locked into a shared lattice with a second, harmless molecule to make it dissolve faster) have been characterised, three of them with biocompatible partners ([Buol et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32660115/)). In practice the material sold is unformulated powder, so absorption is whatever the raw crystal form delivers. Capsules pre-filled by the seller add a weighing step performed by an unaccountable party; bulk powder weighed on a calibrated milligram scale is more verifiable but requires the scale to actually be calibrated. - **Storage:** As a raw crystalline powder with none of the stabilising carrier ingredients a finished medicine would contain, the material degrades unless it is kept sealed, dry, and away from light and heat. Degradation products of an unformulated research chemical are uncharacterised, which makes an old or humidity-exposed batch an unquantifiable rather than merely a weaker one. ## Practical Considerations - **Time to effect:** Nothing happens acutely. A single dose does not measurably affect memory formation; effects in both animal and human data require at least seven days of daily dosing, which also corresponds to the time needed to reach steady state across the parent compound and its longer-lived metabolites. The human trials measured their endpoints at 4 to 12 weeks, so a four-week minimum assessment window is the shortest interval consistent with how the compound was actually studied. - **Common pitfalls:** Dosing upward in search of a stronger effect, when the concentration–response curve peaks at nanomolar levels and declines thereafter. Judging the compound on a single dose. Omitting a choline donor and attributing the resulting headache to the compound being unsuitable. Stacking it with two or three other racetams so that no effect can be attributed. Buying unlabelled powder without a batch certificate. And, most consequentially for men, running it for months without ever measuring the reproductive markers that the entire animal safety literature points at. - **Regulatory status:** Nefiracetam is an unapproved investigational drug. The Japanese marketing application was withdrawn in 2002; it was never filed for approval in the United States or the European Union. It is not a lawful dietary ingredient in the United States, so products marketed as supplements containing it are misbranded, and European medicines control laboratories classify racetam-family compounds sold this way as unauthorised medicines rather than supplements. There is no off-label prescribing route, because there is no on-label product. Import for personal use sits in a grey zone that varies by jurisdiction and has been actively enforced against for related compounds. - **Cost and accessibility:** Cost is not a barrier — bulk powder typically runs from roughly 20 to 60 US dollars for 10 grams, which at 300 mg/day is a multi-month supply, and is trivially cheap relative to the biomarker testing that responsible use requires. Accessibility is the constraint instead: supply is entirely from research-chemical vendors, availability fluctuates with enforcement action, and no supplier is accountable for what is in the container. The economics also explain the evidence gap. The competing treatments in the same clinical territory are inexpensive generics that insurers already reimburse, so no payer and no manufacturer has a financial reason to fund the trials that would resolve the open questions. ## Interaction with Foundational Habits - **Sleep:** Direct and potentially disruptive. Potentiation of nicotinic acetylcholine receptors and increased monoamine turnover both oppose sleep onset, and the practical consideration is timing: the parent compound's 3–5 hour half-life means a dose taken before early afternoon is largely cleared by bedtime, while an evening dose is not. Working in the other direction, nefiracetam's low-concentration potentiation of GABA-A receptors is calming rather than activating, which may be why reports are inconsistent. No overnight sleep-laboratory study has been performed, so the direction of the net effect in any individual is an empirical question best answered by tracking sleep onset latency during the first two weeks. - **Nutrition:** Direct and bidirectional. Food delays absorption without meaningfully changing total exposure, so dosing with or without meals is a tolerability choice rather than an efficacy one. The consequential nutritional interaction is choline: accelerated acetylcholine turnover is the compound's proposed mechanism and also the proposed source of its headache, which is why citicoline at 250–300 mg per dose is the standard pairing. Grapefruit and grapefruit juice sit outside every documented protocol, because they inhibit the CYP3A4 pathway that clears the compound and were a formal exclusion in the National Institutes of Health protocol. Eggs, liver, and fish are the practical dietary choline sources. - **Exercise:** Indirect, with no evidence of blunting. Nefiracetam has no known effect on muscle protein synthesis, on the stem cells that repair muscle after training, or on the adaptive signalling that resistance and endurance training depend on, so the muscle-growth-blunting concern that applies to high-dose antioxidants does not apply here. The relevant practical consideration runs the other way: exercise raises creatine kinase (a muscle enzyme released into the blood after hard training) and can transiently raise liver enzymes, so a monitoring panel drawn within 48 hours of intense training misattributes an exercise effect to the compound. Timing relative to workouts is otherwise unimportant given that the compound does not act acutely. - **Stress management:** Indirect and probably potentiating in the calming direction at low doses. The biphasic GABA-A effect means low concentrations enhance inhibitory tone, which is consistent with the "calm focus" description in user reports, while higher concentrations suppress it and would be expected to do the opposite. No data on cortisol or on the body's central stress-hormone system exist for nefiracetam. The specific practical consideration is that anyone using nefiracetam alongside sedatives that act on GABA — benzodiazepines, phenibut, or alcohol as a stress-management strategy — is combining two agents acting on the same receptor with one of them reversing direction by concentration, which makes the combined effect genuinely unpredictable. ## Monitoring Protocol & Defining Success Because nefiracetam has no approved label, no post-marketing surveillance, and an animal toxicity profile that concentrates on two organ systems, baseline testing is not optional housekeeping — it is the only mechanism by which the principal documented risks could ever be detected. A complete panel drawn before the first dose covers reproductive hormones and semen quality in men, kidney filtration and urine concentrating ability, and liver enzymes. Ongoing testing then repeats the reproductive and renal markers at 12 weeks, which is roughly when structural change had become established in the animal studies, and every 6 months thereafter for as long as dosing continues, with liver enzymes included at each draw. | Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes | |---|---|---|---| | Total testosterone (men) | 600–900 ng/dL | Earliest sensitive marker of the animal testicular lesion | A fasting draw between 07:00 and 10:00 is required; the conventional reference range begins at 264 ng/dL, far below the functional target, so a "normal" result can still represent a substantial personal decline; a low value carries weight only once confirmed on a second morning draw | | Free testosterone (men) | 15–25 pg/mL, or 2.0–3.0% of total | The fraction actually available to tissues | Calculated from total testosterone, sex hormone-binding globulin (SHBG, the carrier protein that binds testosterone in blood), and albumin; only meaningful when run on the same draw as total testosterone | | Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) | LH 2–6 IU/L; FSH 1.5–8 IU/L | Distinguishes a testicular problem from a pituitary one | LH is the pituitary signal driving testosterone production and FSH the signal driving sperm production; in dogs both stayed normal while testosterone fell, so unchanged values do not exclude testicular injury | | Estradiol, sensitive assay (men) | 20–30 pg/mL | Rose in dogs while testosterone fell | Requires liquid chromatography–mass spectrometry; standard immunoassays are unreliable at male concentrations | | Semen analysis (men) | Concentration >40 million/mL; total sperm number >150 million per ejaculate; motility >50%; normal forms >8% | Direct readout of the exact endpoint damaged in two animal species | 2–5 days of abstinence before collection; the conventional World Health Organization lower reference limits sit far below the functional targets — 15 million/mL for concentration, 39 million per ejaculate for total sperm number, 40% motility, 4% normal forms — so a "normal" report can still represent a substantial personal decline; natural variability is high, so a single abnormal result carries little weight until repeated at 4–6 weeks | | Serum creatinine and estimated glomerular filtration rate (eGFR) | eGFR >90 mL/min/1.73 m²; creatinine 0.8–1.1 mg/dL in men, 0.6–0.9 mg/dL in women | Screens for the kidney injury seen in dogs | Creatinine is muscle-mass dependent and overestimates impairment in trained individuals; conventional labs flag eGFR only below 60, which is far too late for this purpose | | Cystatin C | 0.6–1.0 mg/L | Kidney filtration marker independent of muscle mass | Preferable to creatinine in anyone with high muscle mass; best paired with creatinine so that a discordant result flags a measurement artefact rather than real decline | | First-morning urine osmolality | >600 mOsm/kg | Falling urine concentration was the earliest laboratory sign of the canine papillary lesion | The sample is the first void after an overnight fast without fluid intake; rising 24-hour urine volume is the paired observation and can be tracked without a laboratory | | Urinalysis with microscopy | Negative for protein and blood | Bladder lining injury in dogs presented as blood and protein in urine within one week | Dipstick alone is insufficient; microscopy identifies whether red cells are of glomerular or lower-tract origin | | Alanine aminotransferase and aspartate aminotransferase | 10–26 U/L for each | Clearance is almost entirely through the liver, so the liver carries the full metabolic load | Abbreviated ALT and AST; both are liver enzymes that appear in the blood when liver cells are stressed. Conventional upper limits near 40–55 U/L are drawn from populations with prevalent fatty liver and are not a functional target; the draw sits at least 48 hours after intense exercise | | Complete blood count | Within conventional reference ranges | General safety screen for an unapproved compound with no post-marketing surveillance | Abbreviated CBC; a single panel counting red cells, white cells, and platelets. A result that detects nothing is still informative here, because no human blood-safety data for this compound exist at all | Qualitative markers matter more than usual for this compound, because the only human outcomes ever measured were subjective ratings of drive, mood, and function rather than laboratory values. In the protocols where they are tracked, they are recorded daily for the first four weeks and then weekly: - **Drive and initiative:** whether tasks get started without external prompting — the closest everyday analogue to the apathy endpoint that produced nefiracetam's one positive controlled result. - **Cognitive clarity and verbal fluency:** ease of word retrieval and of holding a complex thought, the effects most frequently described in user accounts. - **Working memory in real tasks:** whether multi-step work can be held in mind without external notes, tracked against a pre-dose impression. - **Sleep onset latency and sleep quality:** the most likely early adverse signal and the one most sensitive to dose timing. - **Headache, nausea, and irritability:** the cluster attributed to acetylcholine turnover outstripping choline supply, and the trigger for adding or increasing a choline donor. - **Libido and morning erections:** an early, zero-cost proxy for the hormonal changes the blood panel is designed to catch. Success, defined honestly, is a measurable improvement in drive or cognitive function that survives a four-week discontinuation and re-challenge, with every reproductive and renal marker unchanged from baseline. An improvement accompanied by falling testosterone or rising urine volume is not a success. ## Emerging Research - **Registered trial landscape:** The only nefiracetam trial ever registered on ClinicalTrials.gov is [NCT00001933](https://clinicaltrials.gov/study/NCT00001933), a National Institute of Neurological Disorders and Stroke phase II study of 50 patients with mild to moderate Alzheimer's disease, randomized to nefiracetam or placebo for 20 weeks with an optional seven-month extension, using standardized neuropsychological instruments as the primary measure. It completed in January 2002 and no results were ever posted. No ongoing or planned nefiracetam trial is registered anywhere as of August 2026, which is the single most important fact about the compound's research trajectory: the evidence base is not currently growing. - **Apathy as a re-openable indication:** The 2025 systematic review of post-stroke apathy treatment ([Ruiz-Franco et al., 2025](https://pubmed.ncbi.nlm.nih.gov/41383225/)) concluded that nefiracetam's mixed record reflects dose and the presence of coexisting depression rather than a clean negative, and that pharmacological trials in this area will require multicentre recruitment on a scale no previous attempt achieved. Work in this direction could strengthen the case; the recruitment failure of the 2016 attempt — 13 randomized from 2,514 screened — is the reason it may never be done. - **CaMKII as a drug target:** The mechanistic line that nefiracetam opened has continued independently of the compound itself, with calcium/calmodulin-dependent protein kinase II now pursued as an Alzheimer's target in its own right ([Moriguchi, 2011](https://pubmed.ncbi.nlm.nih.gov/21821968/)). If a more selective CaMKII-directed agent succeeds, it would retrospectively support the mechanism while making nefiracetam obsolete. - **Formulation chemistry:** Thirteen cocrystal forms of nefiracetam have been identified and three characterised with biocompatible coformers, improving dissolution rate and solubility over the raw compound ([Buol et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32660115/)). This is active, recent work with a plausible implication that could cut either way — better absorption could raise exposure into a range where the animal toxicity margins narrow. - **Seizure and neuroprotection models after interrupted blood flow:** Nefiracetam reduced the silent seizures that follow a stroke in rats and protected neurons from two chemical insults that kill them by over-excitation ([Lu et al., 2013](https://pubmed.ncbi.nlm.nih.gov/23603142/)), and lowered inflammatory signalling proteins while normalising the transporters that clear GABA from the synapse in the same model ([Fu et al., 2015](https://pubmed.ncbi.nlm.nih.gov/26584300/)). These are the most recent lines of preclinical work that would strengthen the case, and they remain confined to rodents more than a decade after the clinical programme ended. - **Reproductive toxicity as the decisive unresolved question:** The mechanism of the testicular lesion has been localised to impaired conversion of progesterone to testosterone in Leydig cells ([Shimomura et al., 2004](https://pubmed.ncbi.nlm.nih.gov/15082078/)), but no study has ever asked whether the same interference occurs in human Leydig cells or at human exposures. A single laboratory study on human testicular tissue could weaken or strengthen the case for the compound more decisively than any efficacy trial, and none has been published. - **Analytical surveillance of the grey market:** European and Australian medicines control laboratories are now systematically documenting what is actually in nootropic products ([Vanhee et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40558871/)). This work does not test nefiracetam's pharmacology, but it is the only research programme currently generating new data relevant to what people actually consume, and its findings have consistently weakened confidence in unregulated supply. ## Conclusion Nefiracetam is a synthetic memory compound that never completed the path to approval. Its appeal rests on a coherent laboratory story: it strengthens the chemical signalling nerve cells use to form new connections, and in animals it restores learning disrupted by drugs, by ageing, or by interrupted blood flow to the brain. The human record is much thinner. Controlled trials in people recovering from stroke did not meet their main goals. A signal emerged for reduced apathy — the loss of drive and initiative — in stroke survivors who were also depressed, but a later, very small trial did not reproduce it, and no trial has ever enrolled healthy adults seeking sharper thinking or a longer healthspan. Side effects over a few months appear acceptable, with stomach upset the most common complaint. The unresolved concern is reproductive. Repeated animal studies at high doses found shrinkage of the testes, poorer sperm quality, and lower testosterone, alongside kidney and bladder damage in dogs severe enough to be fatal. Whether any of this applies to humans at the doses people take has never been measured. Almost every dataset here — the laboratory pharmacology, the safety testing, and the pivotal human trials — was produced or funded by Daiichi, the company that developed the compound and stood to profit from it. Nothing sold today is a regulated medicine; identity, purity, and dose depend entirely on the supplier. **[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**